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Abstract
Background: During endochondral bone formation, the hypertrophy of chondrocytes is
accompanied by selective expression of several genes including type X collagen and alkaline
phosphatase. This expression is stimulated by inducers including BMPs and ascorbate. A 316 base
pair region of the type X collagen (Col X) promoter has been previously characterized as the site
required for BMP regulation. The intent of this study was to examine the role of Mitogen Activated
Protein (MAP) and related kinase pathways in the regulation of Col X transcription and alkaline
phosphatase activity in pre-hypertrophic chick chondrocytes.
Results: Using a luciferase reporter regulated by the BMP-responsive region of the type X collagen
promoter, we show that promoter activity is increased by inhibition of extra-cellular signal
regulated kinases 1 or 2 (ERK1/2). In contrast the ability of BMP-2 to induce alkaline phosphatase
activity is little affected by ERK1/2 inhibition. The previously demonstrated stimulatory affect of p38
on Col X was shown to act specifically at the BMP responsive region of the promoter. The
inhibitory effect of the ERK1/2 pathway and stimulatory effect of the p38 pathway on the Col X
promoter were confirmed by the use of mutant kinases. Inhibition of upstream kinases: protein
kinase C (PKC) and phosphatidylinositol 3-(PI3) kinase pathways increased basal Col X activity but
had no effect on the BMP-2 induced increase. In contrast, ascorbate had no effect on the BMP-2
responsive region of the Col X promoter nor did it alter the increase in promoter activity induced
by ERK1/2 inhibition. The previously shown increase in alkaline phosphatase activity induced by
ascorbate was not affected by any kinase inhibitors examined. However some reduction in the
alkaline phosphatase activity induced by the combination of BMP-2 and ascorbate was observed
with ERK1/2 inhibition.
Conclusion: Our results demonstrate that ERK1/2 plays a negative role while p38 plays a positive
role in the BMP-2 activated transcription of type X collagen. This regulation occurs specifically at
the BMP-2 responsive promoter region of Col X. Ascorbate does not modulate Col X at this
region indicating that BMP-2 and ascorbate exert their action on chondrocyte hypertrophy via
different transcriptional pathways. MAP kinases seem to have only a modest effect on alkaline
phosphatase when activity is induced by the combination of both BMP-2 and ascorbate.
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During skeletal development and growth, bone formation
occurs either by intramembraneous or endochondral
bone formation. In endochondral bone formation, which
occurs at the growth plates of long bones, cartilage is
formed first, then the chondrocytes undergo a prolifera-
tive phase followed by hypertrophy, changes in gene
expression, and matrix calcification, after which the carti-
lage is replaced by bone. Although generally referred to as
chondrocyte hypertrophy, cell enlargement is just one
manifestation of the more complex process of chondro-
cyte maturation, which can be considered an end-stage of
chondrocyte differentiation. It is important to define the
mechanisms that induce chondrocyte maturation, not
only to understand bone development, but also to help
prevent hypertrophy and ossification during cartilage tis-
sue engineering.
Hypertrophic chondrocytes are characterized by their
increased levels of alkaline phosphatase (ALP), reduced
levels of type II and IX collagens, and the emergence of
type X collagen (Col X), which is a specific marker of
hypertrophy [1,2]. Ascorbate and bone morphogenetic
proteins (BMPs) are among the factors previously shown
to be inducers of ALP gene expression in chondrocytes.
Either of these inducers alone will elevate ALP activity in
chondrocytes derived from pre-hypertrophic regions of
avian cartilage, but the combined effect of BMP and ascor-
bate is more than additive [3]. In early studies with avian
chondrocytes, ascorbate-induced increases in type X colla-
gen expression appeared to parallel increasing alkaline
phosphatase activity, suggesting that both Col X and ALP
might be controlled by common pathways [4]. However,
analyses of BMP-stimulated hypertrophy suggested that
ALP activity gradually increased over a 3 day period, while
Col X mRNA reached maximal levels within 24 h. Experi-
ments in which pre-hypertrophic chick chondrocytes were
transfected with luciferase constructs regulated by
sequences from the avian type X collagen gene demon-
strated that a "b2" region 2.6-2.0 kilobases upstream of
the ColX transcription start site, when joined to 640 base
pair (bp) region of the proximal promoter, was transcrip-
tionally activated by BMP-2, -4, and -7 [5]. Northern blot
analyses after cyclohexamide treatment showed that new
protein synthesis is not required for BMP-induced Col X
expression [3]. Additional studies indicated that the
mechanism for type X collagen promoter regulation prob-
ably involves BMP-activated Smads interacting with a
Runx2/Cbfa1 transcription factor [6], and that retinoic
acid stimulation of Col X expression is via the same 316
bp region [7,8]. Although long-term (4–7 day) treatment
of chondrocytes with ascorbate results in increased levels
of type X collagen mRNA [9], there is no data concerning
the ability of ascorbate to regulate the type X collagen
promoter.
In osteoblastic cells, BMPs and ascorbate have been
shown to operate via mechanisms that at least partly
involve mitogen activated protein kinases (MAP kinases).
For example, ascorbate promotes extracellular matrix pro-
duction which, in turn, activates the extracellular-signal
regulated kinases, (ERK1/2 or p42/ p44) in an osteoblas-
tic cell line [10]. MAP kinases including ERK1/2 [11,12],
p38 [13] and PI3 (phosphatidylinositol 3-) kinase [14]
have also been reported to be required for BMP-depend-
ent induction of osteoblast differentiation. However,
these pathways can act oppositely in certain BMP induced
processes such as osteocalcin synthesis by osteoblasts
[15].
In general, MAP kinase pathways involving ERK1/2 stim-
ulate proliferation, growth and differentiation, whereas
those that stimulate p38 kinase lead to differentiation and
apoptosis [16]. In early stages of chondrocyte differentia-
tion, an increase in p38 and decrease in ERK1/2 activity is
required for the progression to cartilage nodule formation
in chick limb buds [17]. In hypertrophying chondrocytes
p38 has been shown to be required for Col X mRNA syn-
thesis [18]. In apoptosis of articular chondrocytes [19]
and other cell types [20], ERK1/2 inhibits and p38 stimu-
lates the apoptotic pathway.
Chick sternal chondrocytes are a popular model for the
study of chondrocyte maturation because under normal
development chondrocytes from the cephalic portion of
the sternum undergo hypertrophy followed by minerali-
zation and bone formation, whereas the caudal portion
remains as cartilage [3,8]. In this study we investigate the
roles of ERK1/2, p38 and two upstream pathways, protein
kinase C (PKC) and PI3 kinase, in the maturation of chick
prehypertrophic sternal chondrocytes induced by BMP-2
and ascorbate.
Results
ERK signaling inhibits transcription of the BMP-2 
responsive type X collagen promoter but is not involved in 
the regulation of alkaline phosphatase activity
Studies with the ERK1/2 inhibitor U0126 indicated that
blocking ERK1/2 signaling increased the activity of the
type X collagen promoter but had no effect on alkaline
phosphatase (ALP) activity in chick cephalic sternal
chondrocytes (Fig. 1). Cells transfected with luciferase
reporter plasmid containing the BMP-responsive b2/640
region of the Col X promoter showed a 3-fold (p < 0.05)
increase in luciferase expression, as a ratio to the pRL null
control vector, after the addition of 4 µM U0126, both
with and without exogenous BMP-2 (Fig 1A). In contrast
neither basal nor BMP-stimulated ALP activity were signif-
icantly changed in the presence of U0126 (Fig. 1B).Page 2 of 10
(page number not for citation purposes)
Cell Communication and Signaling 2005, 3:3 http://www.biosignaling.com/content/3/1/3ALP activity was highly variable between cell isolates and
is expressed here normalized to BMP-2 treated controls
for the purpose of combining experiments, typical ALP
values ranged from approximately 0.5–2 nmol/min/µg
DNA in controls to between 4 and 12 nmol/min/µg DNA
in BMP-2 treated cultures.
The effects of altered ERK1/2 signaling on Col X promoter
activity in chick sternal chondrocytes was further studied
both by transfection with mutant kinases and by treat-
ment with additional kinase inhibitors. Col X promoter
activity was increased, both in the presence and absence of
BMP-2, when the mitogen-stimulated ERK pathway was
suppressed by transfecting chondrocytes with dominant
negative ERK-2 (Figs. 2A, 2B). Conversely, stimulating the
ERK1/2 pathway by over-expressing constitutively active
MEK1, an upstream kinase of ERK1/2, decreased pro-
moter activity by 50% (p < 0.05) and in BMP-2 treated
cells it eliminated any BMP response.
As seen with the ERK1/2 inhibitor U0126, treatment with
the more specific ERK1/2 inhibitor PD098059 increased
b2/640 Col X promoter activity, in the presence of BMP-2
(Fig. 2D). Dose response experiments indicated that con-
centrations of PD98059 as low as 10 µM significantly
increased luciferase expression 2-fold (p < 0.001) in BMP-
treated cells, but not in the absence of BMP-2 (Fig. 2C). At
a higher does, 50 µM, of PD90859 luciferase levels in
BMP-2 treated cells were 10–20 fold higher (p < 0.005)
than BMP-containing cultures without inhibitor (Fig.
2D), at this dose PD90859 also stimulated the promoter
in the absence of BMP-2 (Fig. 2C).
p38 MAP kinase signaling contributes to the response of 
the type X collagen promoter to BMP-2
Transfection with dominant negative p38 caused a
decrease in Col X promoter activity in BMP-2 treated
cephalic chondrocytes, reducing activity to half of that
seen in BMP-2 treated controls (p < 0.005) and eliminat-
ing the BMP-2 response (Figs. 2A and 2B). Similarly, 1 µM
SB 203580, an inhibitor of p38, significantly decreased
BMP-stimulated promoter activity (Fig. 2D), but had little
effect on promoter activity in the absence of BMP-2 (Fig.
2C).
Inhibiting PKC and PI3 kinases increases type X collagen 
promoter activity
Addition of either PI3 kinase inhibitor or PKC inhibitor
resulted in similar stimulation of the collagen type X pro-
moter. Calphostin C, a PKC inhibitor, increased activity in
BMP-2 treated cells more than 2-fold, an effect similar to
that seen with the ERK1/2 inhibitor PD98059 at 10 µM
(Fig. 2D). Similarly, 50 µM LY294002, a PI3 kinase inhib-
itor, stimulated the b2/640 promoter approximately 2-
fold (Fig. 2D). However, both of these inhibitors also
increased transcription of the collagen type X promoter in
non-BMP-2 treated cells to levels as high as seen with the
combination of BMP-2 and the respective inhibitor treat-
ment (Fig. 2C).
Kinase inhibitor effects on viable cell number
To assess the possible effects of protein kinase inhibitors
on cell proliferation and survival, we measured relative
numbers of live cells using a tetrazolium (MTS) assay. The
Effects of BMP-2 and the ERK inhibitor, UO126, on the Col X promoter and lkalin phosphatase activity in chick ce halic st nal chondrocyteFigure 1
Effects of BMP-2 and the ERK inhibitor, UO126, on 
the Col X promoter and alkaline phosphatase activ-
ity in chick cephalic sternal chondrocytes. A: Activity 
of the b2/640 type X collagen promoter; 24 hrs after seeding 
cells were transfected with PGLb2/640 and pRLnull luciferase 
vectors, 5 hrs after transfection 4 µM U0126 or vehicle 
(DMSO) was added. BMP-2 was added to selected wells after 
a further hour. Values are mean ± S.D of the mean ratio of 
promoter to empty vector fluorescence units, for 6 experi-
ments assayed in triplicate. B: Alkaline phosphatase activity; 
24 hrs after seeding, medium was changed and 4 µM U0126 
or vehicle was added. BMP-2 was added to selected wells 
after a further hour. Cell extracts were prepared 72 hrs 
later. Data was obtained using 5 different isolates of 
chondrocytes assayed in triplicate. Values are mean ± SEM of 
12–15 samples normalized to within experiment controls 
treated with BMP-2 but no inducers, *:p < 0.01 group differs 
from non BMP-2 treated group within inhibitor treatment, +: 
p < 0.05 that group differs from group with no UO126.
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with and without BMP-2 and/or ascorbate, had cell num-
bers within 10% of untreated controls (data not shown).
Ascorbate has no effect on the type X collagen promoter 
and stimulates alkaline phosphatase activity regardless of 
kinase inhibitor treatment
We examined the effect of 75 µM ascorbate-2-phosphate
on the activity the Col X promoter in cultures treated with
kinase inhibitors. Col X promoter activity was unaffected
by addition of ascorbate, and 4 µM of the ERK1/2 inhibi-
tor U0126 increased promoter activity to comparable lev-
els both with and without ascorbate (Fig. 3A).
The increase in alkaline phosphatase activity caused by 
adding BMP-2 to ascorbate treated cultures is reduced by 
ERK inhibitors
ALP activity in the absence of exogenous BMP was stimu-
lated at least 2-fold in ascorbate-treated cultures without
inhibitors, as previously reported, and this stimulation
was not significantly affected by addition of either ERK1/
2 or p38 inhibitors (Fig. 3B). In cultures treated with
Effects of MAP kinase manipulation on b2/640 type X collagen promoter activity, in chick cephalic sternum chondrocytesFigure 2
Effects of MAP kinase manipulation on b2/640 type X collagen promoter activity, in chick cephalic sternum 
chondrocytes. A and B: Mutant kinases; 24 hrs after seeding, cells were transfected with luciferase vectors and 0.5–1 µg 
mutant kinase DNA. After 5 hrs medium was changed (A) or medium changed and BMP-2 added (B). C and D: Inhibitor treat-
ments; 5 hours after transfection with luciferase vectors, medium was changed and kinase inhibitor or vehicle (DMSO) was 
added as indicated. In D 30 ng/ml BMP-2 was added one hr after medium change. Data obtained using at least 2 independent 
isolates of chondrocytes, assayed in triplicate. Values are mean ± SEM of luciferase ratios of type X collagen promoter activity 
to control vector, normalized to BMP-2 treated controls. *:p < 0.05 that luciferase ratio differs from non BMP-2 treated group, 
+: p < 0.05 that luciferase ratio differs from group with no MAP kinase manipulation.
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Cell Communication and Signaling 2005, 3:3 http://www.biosignaling.com/content/3/1/3Effects of ascorbate and MAP kinase inhibitors on the Col X promoter and alkaline phosphatase activity in chick cephalic ster-nal hondro ytesFigure 3
Effects of ascorbate and MAP kinase inhibitors on the Col X promoter and alkaline phosphatase activity in 
chick cephalic sternal chondrocytes. A: Activity of the b2/640 type X collagen promoter; 24 hrs after seeding cells were 
transfected with luciferase vectors, 5 hrs after transfection 4 µM U0126 or vehicle were added. Ascorbate was added to 
selected wells after a further hour. Values are mean ± S.D of the mean ratio of promoter to empty vector fluorescence units, 
for 3 experiments assayed in triplicate. B: Alkaline phosphatase activity; 24 hrs after seeding, medium was changed and 4 µM 
U0126 or vehicle was added. Ascorbate or ascorbate with BMP-2 was added to selected wells after a further hour. Cell 
extracts were prepared 72 hrs later. Data was obtained using 5 different isolates of chondrocytes assayed in triplicate. Values 
are mean ± SEM of 12–15 samples normalized to within experiment controls treated with BMP-2 but no inducers. *: p < 0.05 
that group differs from non-supplemented group within inhibitor treatment. The increase in ALP caused by BMP-2 addition is 
shown, this increase is significantly smaller in UO126 treated cells, +:p < 0.05.
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resulted in ALP levels that were <60% of the level seen in
cells without inhibitor (Fig. 3B). The increase caused by
BMP-2 addition, relative to ascorbate only-treated cul-
tures was significantly reduced by treatment with U0126
(p < 0.05). The p38 inhibitor SB203580 did not cause a
statistically significant inhibition of alkaline phosphatase
activity. PI3 kinase and PKC inhibitors had no significant
effects on ALP activity (data not shown).
Discussion
The present studies demonstrate that ERK1/2 inhibition
increases activity of the BMP responsive region of the type
X collagen promoter. This indicates that ERK1/2 signaling
interferes with the ability of BMP-induced signals to stim-
ulate type X collagen transcription. Interestingly ERK1/2
has also been shown to inhibit type I collagen expression
in an osteoblastic cell line [21] suggesting there may be a
common pattern of ERK1/2 inhibition of collagen tran-
scription pathways.
In contrast to the stimulatory effects of inhibiting the ERK
pathway, p38 inhibition blocked BMP-stimulated Col X
promoter activity. Zhen et al. [18] and Beier and Luvalle
[22] also showed that p38 signaling is important for regu-
lation of Col X expression, Beier and Luvalle suggested
that the proximal promoter contained a site for p38
action. Here, we have confirmed these results and nar-
rowed the region of p38 responsiveness to within the
region of the Col X promoter that is also BMP responsive.
While the classical pathway for BMP signaling is via acti-
vation of R-Smads, there is also evidence for BMP signal-
ing via a TGF-activated kinase (TAK1) leading to p38
signaling [23-26]. However, in preliminary experiments
Smad1 over-expression increased BMP-stimulated Col X
promoter activity even in the presence of DN-TAK1 (data
not shown). This suggests that BMP-activated Smad sign-
aling and not TAK1 signaling is the major factor in Col X
promoter regulation. Taken together these data suggest
that the role of p38 is as a co-activator of Smads or Runx-
2 rather than a downstream effector of BMP signaling.
Inhibiting either protein kinase C (PKC) or phosphati-
dylinositol 3-kinase (PI3 kinase) increased type X colla-
gen promoter activity both in BMP-2 treated cultures and
controls. Both PKC and PI3 kinase have been reported to
negatively regulate p38 [18] and positively regulate ERK1/
2 [20,27,28]. The complex effects in which these kinases
stimulate basal Col X promoter activity but inhibit BMP-2
from stimulating additional activity may be due to their
simultaneously affecting both of these pathways.
Although alkaline phosphatase expression, like type X col-
lagen expression, increases during chondrocyte hypertro-
phy and is stimulated by BMPs, its regulation clearly
differs from Col X in several respects. ERK1/2 inhibition
has little effect on the ALP activity induced by BMP-2 or
ascorbate acting alone and reduces the ability of BMP-2 to
further stimulate ALP activity in ascorbate treated cultures.
Inhibiting p38 does not have a clear effect on BMP-stimu-
lated alkaline phosphatase activity in this model although
it has been shown to reduce ALP activity in long-term
(12–15 day) micromass cultures [29].
Preliminary studies with cyclohexamide indicate that new
protein synthesis is required for the up-regulation of alka-
line phosphatase mRNA in response to BMP-2. We pro-
pose that these differences reflect a direct Smad-mediated
effect of BMPs on type X collagen expression and an indi-
rect effect on ALP expression.
A mechanism which could account for the observed
effects of ERK and p38 signaling on expression of type X
collagen and ALP is presented in Fig. 4. The simplest
explanation for our observation that a decrease in ERK1/2
signaling causes increased type X collagen promoter activ-
ity is that ERK1/2 can phosphorylate the linker region of
BMP-activated Smads, preventing nuclear translocation of
activated Smads, as suggested by Kretzschmar et al. [30].
Alternatively, products of ERK1/2 signaling may act
directly on a silencer within the type X collagen promoter
such as the region identified by Beier et al. [31] at 2864-
2410 base pairs which would overlap with our b2-con-
taining construct (2649 -2007).
Evidence that BMP stimulation of type X collagen requires
both activated R-Smads and Runx2 has been previously
reported [5,7]. Little is known concerning kinase
phosphorylation of Runx2, except for the report that ERK
phosphorylates Runx2 and increases its binding to the
osteocalcin promoter [32] in osteoblasts. If ERK phospho-
rylation of Runx2 were required for BMP-stimulated type
X collagen transcription, we might expect ERK1/2 inhibi-
tion to decrease the activity of the Col X promoter. How-
ever, as ERK1/2 inhibition increases Col X promoter
activity while partially inhibiting ALP we propose that the
Runx2-Smad complex binding to the Col X promoter may
not be phosphorylated by ERK1/2, but that ALP expres-
sion does require Runx2 phosphorylated by ERK1/2.
As well as its demonstrated role in Col X expression as
found here and by [18,31], there are also reports that p38
inhibitors block osteoblast differentiation [33,34].
Because Runx2 plays an important role in both osteogen-
esis and chondrocyte maturation, we have suggested that
p38 may function in Runx2 expression, activation or
nuclear translocation. However, there are many other pos-
sible roles, including the suggestion that p38 is down-
stream of BMP-activated Smad signaling [35].Page 6 of 10
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hypertrophy has also been shown to act at the BMP-2
responsive b2 region of the type X collagen promoter,
however ascorbate, which does produce an increase in
type X collagen mRNA expression [4], does not seem to
have any effect on this promoter region. These results, in
combination with previous findings that Col X mRNA
expression only occurs after 4–9 days stimulation with
ascorbate [9], suggest that the effects of ascorbate on reg-
ulation of type X collagen expression are via a separate
mechanism than BMP stimulation and are probably
indirect.
Conclusions
Elucidating the signaling pathways by which chondro-
cytes are driven to hypertrophy is necessary in order to
better understand skeletal development, cartilage disease
and improve the design of tissue engineered cartilage. We
showed here that the ERK1/2 pathway inhibits type X col-
lagen production by either directly or indirectly acting at
the BMP responsive region of the promoter. p38 kinase
signaling stimulates type X collagen transcription at the
same promoter region, probably in conjunction with
BMP-2 activated Smads. The factor upstream of p38 in this
stimulatory pathway is unknown. Alkaline phosphatase
activity is likely to be regulated in a different way from
type X collagen since MAP kinases do not contribute in
the same way to this pathway. Although ascorbate and
Possible mechanism for kinase involvement in BMP stimulated type X collagen expressionFigure 4
Possible mechanism for kinase involvement in BMP stimulated type X collagen expression. ERK1/2 is proposed 
to suppress activated Smad translocation to the nucleus as described by Kretschmer et al. [30] and thereby inhibit Col X tran-
scription. ERK-specific Runx2 phosphorylation is required for regulation of typical osteoblastic genes but may not be required 
for Col X expression. However p38 facilitates Col X transcription, possibly via Runx2 phosphorylation and although was not 
shown to be involved in short term increases in ALP in our model, has been shown to be involved in long term increases in 
ALP over 15 days of chondrocyte differentiation in culture (question mark) [29].
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does not act at the same region of the Col X promoter as
BMPs.
Methods
Inhibitors and plasmids
The ERK1/2 inhibitor PD98059, which blocks the
upstream kinase (MEK1) of ERK1/2, the p38 inhibitor
SB203580, and the PKC inhibitor Calphostin C were
obtained from Sigma (St. Louis, MO). UO126, also a
MEK1 inhibitor, was obtained from Biomol (Plymouth
Meeting, PA) and LY294002, a phosphatidylinositol 3-
(PI3) kinase inhibitor from Cell Signaling Technology
(Beverly, MA). Plasmids were kindly donated as follows:
constitutively active MEK1 from Michael Webber (Univer-
sity of Virginia); dominant negative p38 [36] from Roger
Davis at the Howard Hughes Medical Institute, University
of Massachusetts Medical School, dominant negative
ERK2 [37] from Melanie Cobb at University of Texas
Southwestern Medical Center.
Cell Culture
Chondrocytes were cultured as previously described [3].
Cephalic and caudal sternal chondrocytes were isolated
from 15 day chick embryos and cultured for 5 days. Dis-
section of chick cartilage was performed under a Univer-
sity of Pennsylvania IACUC exemption. On day 5 non-
adherent cells were removed and plated in 12 well plates
at 300,000 cells /well in DMEM supplemented with 10%
NuSerum, 2 mM L-glutamine, 100 U/ml penn/strep and 4
U/ml hyaluronidase, to promote cell attachment.
Transfection of cephalic (pre-hypertrophic) sternal 
chondrocytes
On day 1 of secondary culture (24 hrs after plating) the
cell layer was washed in HBSS and the media changed to
DMEM supplemented with 10% FBS in place of NuSe-
rum. Cells were co-transfected with pGL2 plasmid con-
taining the b2/640 type X collagen promoter region
attached to a firefly luciferase reporter (0.2–1 µg/well)
(Promega, Madison, WI) and pRL null plasmid attached
to a renilla luciferase reporter (0.4 µg/well) (Promega)
which served as a transfection control [5]. When appropri-
ate, mutant plasmids were added at 0.5 or 1 µg/well along
with the luciferase vectors. Luciferase and mutant kinase
plasmids were transfected either using CaPO4 precipita-
tion or Fugene transfection reagent at 6 µl/ml (Promega).
Since preliminary experiments using green fluorescent
protein showed that Fugene was more effective in terms of
numbers of cells transfected, this method was used for the
majority of the experiments; however, relative outcomes
between controls and treated cells were not affected by the
transfection method.
Transfection proceeded for 5 hrs after which the cell layer
was rinsed twice in HBSS and cultured with serum free
medium (DMEM with 2 mM L-glutamine, 100 U/ml
penn/strep, 4 U/ml hyaluronidase, 60 ng/ml insulin, 1
mM cysteine, and 10 pM triiodothyronine). Some wells
were supplemented with 75 µM ascorbate-2-phosphate
(Wako, Takara, Japan) or 30 ng/ml human recombinant
BMP-2 (Wyeth, Cambridge, MA). Where inhibitors were
used they were added at this point and cells incubated for
1 hr before the addition of BMP-2. Cells were cultured for
a further 48 hours, then lysed and assayed using a dual
luciferase assay kit (Promega).
Alkaline Phosphatase Assay
For alkaline phosphatase assays, cells were switched to
serum free medium on day 1 of secondary culture, inhib-
itors were added and cells incubated for 1 hr before the
addition of ascorbate or BMP-2, as described for the luci-
ferase assay. Cells were cultured for a further 72 hrs and
then rinsed twice in HBSS. Cells numbers were assayed
either by DNA quantification (CyQUANT cell prolifera-
tion assay kit, Molecular Probes, Eugene, OR) or by MTS
tetrazolium salt assay of mitochondrial activity (Cell Titer
96 AQueous One Solution Cell Proliferation Assay,
Promega). When MTS was used, a 1:10 dilution of MTS
was applied in phenol red-free media for 30–60 minutes,
200 µl of media plus MTS was transferred to a 96 well
plate and assayed in a 'Multiskan ascent' plate reader
(Thermolabsystems, Franklin, MA). The cell layer was
then washed twice in HBSS and extracted with 0.15 M
Tris, pH 9 with 0.1 mM ZnCl2, 0.1 mM MgCl2 and 1% Tri-
ton X-100 for 30 mins at 37°C, followed by overnight
storage at 4°C. A sample of the cell lysate was reacted with
p-nitrophenyl phosphate substrate in 1.5 M Tris buffer pH
9 with 1 mM ZnCl2 and 1 mM MgCl2. Phosphatase activ-
ity was measured specrophotometrically at 410 nm with 1
absorbance unit equivalent to 64 nmol of product. For
DNA analysis, cells were trypsinized and a subsample of
cell suspension centrifuged, the cell pellet lysed with the
CyQUANT lysis buffer and the fluorescent DNA dye
added. The resulting solution was transferred to a 96 well
plate and DNA assayed fluorometrically. The remaining
cells were extracted for the alkaline phosphatase assay as
above. Alkaline phosphatase enzyme levels were calcu-
lated as nmol p-nitrophenol product per minute normal-
ized to MTS units or µg DNA.
Statistical analysis
Statistics were performed using Minitab™ software. After
expressing results as a ratio of experimental/control
within each experiment, the data from at least 3 experi-
ments were combined. The combined data was tested for
normality using the Anderson-Darling test. Normally dis-
tributed or non-parametric data were tested for differences
between treatments using two-sample Students t-test orPage 8 of 10
(page number not for citation purposes)
Cell Communication and Signaling 2005, 3:3 http://www.biosignaling.com/content/3/1/3the Mann-Whitney test respectively. Where groups of
experiment means were compared a paired t-test was
used.
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